Manufacturing Novartis unveils North Carolina API plant as final piece of $23B US expansion BioSpaceThe new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) BioSpace The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites. Read full story Post navigation Previous: Amgen positions MariTide as potential ‘best monthly’ obesity drugNext: Pfizer, Arvinas join SERD club with Veppanu approval Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026
